Decoding neurons to unlock breakthrough cns therapeutics

Mission

To accelerate discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease - all powered through Quiver's innovation engine and strategic partnerships.

The opportunity

Brain health is a growing global crisis, but neurological drug development continues to see the lowest success rates. Most failures trace back to weak targets, unexpected toxicities, and misaligned patient selection—issues driven by the historical lack of scalable human-relevant models, reliable neural measurements, and the computational power needed to decode complex brain biology.

Quiver's Solution

Our value proposition is simple: safer, more effective CNS drugs, discovered faster and at lower cost, with human relevance built in from day one. Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.

quiver purple, pink, and red brain
01
Models
Patient-derived stem-cell models enhance translatability by capturing disease phenotypes.
02
signals
All-optical electrophysiology that scalably assesses neuron function at the gold-standard resolution, but with >10,000x throughput 9.6B+ action potentials from >126M neurons and counting
03
insights
AI models mine our high-dimensional data to (a) establish disease phenotypes, (b) assess drug efficacy, (c) match drugs to targets, and (d) avoid unwanted, off-vector toxicity 
quiver purple, pink, and red brain

Quiver's Solution

Our value proposition is simple: safer, more effective CNS drugs, discovered faster and at lower cost, with human relevance built in from day one. Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.

01
Models
Patient-derived stem-cell models enhance translatability by capturing disease phenotypes.
02
signals
All-optical electrophysiology that scalably assesses neuron function at the gold-standard resolution, but with >5,000x throughput 1B action potentials from >25M neurons in <6 months
03
insights
AI models mine our high-dimensional data to (a) establish disease phenotypes, (b) assess drug efficacy, (c) match drugs to targets, and (d) avoid unwanted, off-vector toxicity 

OUR PLATFORM-POWERED THERAPEUTIC PIPELINE

Disorder/Target
Discovery
Pre-clinical
Clinical
Partner
Chronic Pain Disorders
Nav1.7 (ASO)
Nav1.8 (ASO)
Dual Nav1.7 / 1.8 (ASO)
Nav1.8 (Small Molecule)
Wholly Owned
Seizure and Neurodevelopment Disorders
Dup15q Syndrome - UBE3A (ASO)
DEE4 - STXBP1 (ASO)
SYNGAP (ASO)
Tuberous Sclerosis Complex - TSC2 (Small Molecule)
Fragile X Syndrome – (ASO)
Wholly Owned
We welcome partnership opportunities with other organizations seeking to develop novel therapeutics for serious diseases or with parties interested in leveraging our unique platform capabilities
Read Article
Read Article
Read Article